Posted on 4/24/18
Valeritas Prices $24 Million Public Offering of Common Stock
BRIDGEWATER, N.J., April 24, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with type 2 diabetes V-Go® Wearable Insulin . . .
Posted on 4/24/18
Compass Health Systems Selects Meridian Medical Management for Robotic Automation
WINDSOR, Conn., April 24, 2018 (GLOBE NEWSWIRE) -- Meridian Medical Management today announced that Compass Health Systems, a behavioral and medical services organization, has selected Meridian . . .
Posted on 4/24/18
Celgene: Will Tremfya Punish Otezla Too?
[Editor's note: An earlier version of this article referenced Pfizer's Xeljanz in relation to psoriasis. However, Xeljanz only treats psoriatic arthritis. This has been corrected.]Johnson & . . .
Posted on 4/24/18
Celgene: Bold Pursuits In Science With 24.66% Discount
Celgene Corporation (NASDAQ:CELG) is one of the most appealing stocks for value investors within the pharmaceuticals sector because of its good value with a proven track . . .
Posted on 4/24/18
Johnson & Johnson's Top-Line Growth Isn't What It Seems
Johnson & Johnson (NYSE:JNJ) recently reported that its revenue soared 12.6% to $20 billion in the first quarter. However, that revenue growth rate comes with an . . .
Posted on 4/23/18
Mountainside Medical Group Adds New Physicians
MONTCLAIR, N.J.--(BUSINESS WIRE)--Mountainside Medical Group announced today the addition of three new physicians, Pulmonologist Juhayna Davis, M.D., Endocrinologist Anjali Grover, M.D., andOB/GYNspecialist Vanessa Parisi, D.O., expanding . . .
Posted on 4/23/18
Spok and Bernoulli Health Partner
SPRINGFIELD, Va.--(BUSINESS WIRE)--Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK) and the leader in healthcare communications, today announced an alliance with Bernoulli® . . .
Posted on 4/23/18
Pernix Therapeutics Announces Participation in Lead Bid for Acquisition of Worldwide Rights to Contrave for Weight Loss
MORRISTOWN, N.J, April 23, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that it has agreed to participate in . . .
Posted on 4/23/18
Cambrex Completes New $3.2 Million Analytical Research & Development Laboratory at its High Point, NC Facility
EAST RUTHERFORD, N.J., April 23, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today . . .
Posted on 4/23/18
Pfizer Provides Update on Proposed Trastuzumab Biosimilar
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it received a Complete Response Letter (CRL) from the United States Food and Drug Administration (FDA) in response . . .
Posted on 4/23/18
Why Stanley Black & Decker, ManpowerGroup, and Sage Therapeutics Slumped Today
Friday was a poor day on Wall Street, as the Dow Jones Industrials fell 200 points and other major benchmarks lost about 1%. Rising bond yields . . .
Posted on 4/23/18
Johnson & Johnson's First-Quarter 2018 Earnings Review
Johnson & Johnson (NYSE:JNJ), a staple in investor portfolios, has plenty of news for us to digest in its first-quarter earnings release.In this episode of The . . .
Posted on 4/23/18
Johnson & Johnson Sells Off After Earnings
Johnson & Johnson (JNJ) reported revenue of $20.01 billion and eps of $2.06. The company delivered a revenue and earnings beat, but the stock is off . . .
Posted on 4/20/18
3 Drugs That Are Moving the Needle at Johnson & Johnson
Johnson & Johnson (NYSE:JNJ) reported first-quarter 2018 results this week that outpaced industry watchers' forecasts. Its $20 billion in quarterly revenue clocked in over $600 million . . .
Posted on 4/19/18
Targeted Oncology To Launch Virtual Tumor Board
CRANBURY, N.J.--(BUSINESS WIRE)--Targeted Oncology™, a print and digital resource that offers content and expert opinions on precision medicine in oncology, will launch the first Expert Perspective: . . .
Posted on 4/19/18
Johnson & Johnson: Steady As She Goes
Johnson & Johnson (JNJ) really does not require an introduction as the well-run giant continues to deliver on steady returns for long-term investors. A strong multi-year . . .
Posted on 4/18/18
Interpace Diagnostics Enters Agreement with One of the Largest, Integrated Health Systems in the US
PARSIPPANY, N.J., April 18, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically . . .
Posted on 4/18/18
Johnson & Johnson: Good Start Of The Year But Valuation Is Still Not Cheap Enough
Johnson & Johnson reported better than expected Q1 2018 results.The corporate signals have been mixed with some positive messages related to Pharmaceutical Division but still unexciting . . .
Posted on 4/18/18
Pfizer Reportedly Rules Out Bristol-Myers Squibb Deal -- Here Are 3 Better Acquisition Targets
So Pfizer (NYSE:PFE) doesn't want to buy Bristol-Myers Squibb (NYSE:BMY) after all? That's what appears to be the case.Pfizer chairman and CEO Ian Read told Citi . . .
Posted on 4/18/18
Johnson & Johnson: Recovering From A Deep Correction, Beats Earnings Estimates
Johnson & Johnson (NYSE:JNJ) closed Friday at $130.62, down 6.5% year to date and in correction territory, 11.9% below its all-time intraday high of $148.33 on . . .
Posted on 4/18/18
Merck Posts Another Advance In The Lucrative Lung Cancer Market
Recently, Merck (MRK) presented results for its phase 3 lung cancer study. It noted that patients in the front-line lung cancer setting on a Keytruda/chemo combo . . .
Posted on 4/18/18
Johnson & Johnson (JNJ) Q1 2018 Earnings Conference Call Transcript
IMAGE SOURCE: THE MOTLEY FOOL.Johnson and Johnson (NYSE:JNJ)Q1 2018 Earnings Conference CallApril 17, 2018, 8:30 p.m. ETContents:Prepared RemarksQuestions and AnswersCall ParticipantsPrepared Remarks:OperatorGood morning. Welcome to Johnson . . .
Posted on 4/18/18
Zytiga, Stelara Lift Johnson & Johnson's Sales
It's hard to find a broader-based healthcare company than Johnson & Johnson (NYSE:JNJ). With exposure to everything from the most sophisticated medical devices and specially formulated . . .
Posted on 4/17/18
Johnson & Johnson Reports 2018 First-Quarter Results
Johnson & Johnson (NYSE: JNJ) today announced sales of $20.0 billion for the first quarter of 2018, an increase of 12.6% as compared to the first . . .
Posted on 4/17/18
Pfizer's DMD Drug Could Spell Long-Term Trouble For Sarepta
Pfizer Inc. (NYSE:PFE) has dosed its first patient in a Phase 1 trial for its Duchenne muscular dystrophy drug PF-06939926. The asset was acquired during Pfizer’s . . .

